BioSpace News Archive

Lunit announced the presentation of five abstracts highlighting the effectiveness of its AI-biomarker platform - Lunit SCOPE - at the European Society of Medical Oncology Congress 2022, held in Paris from September 9 to 13.

Dizal reported the promising safety and pharmacokinetic data from the global Phase I study of DZD1516 in patients with HER2 positive metastatic breast cancer who relapsed from multiple prior treatments at the 2022 European Society for Medical Oncology Annual Meeting.

Dizal announced positive topline results from the first pivotal study of sunvozertinib in platinum-pretreated NSCLC Patients with EGFR exon20ins mutations at the European Society for Medical Oncology Annual Meeting.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced positive data from its ongoing Phase 3 study evaluating Clover’s SCB-2019 as a universal COVID-19 booster vaccine candidate.

Results from a Phase 3 open-label extension trial demonstrated the efficacy and safety profile of Dupixent® as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma with evidence of type 2 inflammation.

Regeneron Pharmaceuticals, Inc. and Sanofi announced results from a Phase 3 open-label extension trial demonstrating the efficacy and safety profile of Dupixent® as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma with evidence of type 2 inflammation.